ArticleMolecular biology reports2025
Combined nicotinamide riboside and magnesium-l-theanine protects against chronic stress-induced gut-liver injury by modulating NAD⁺ and metabolic pathways.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multisystem pathology in chronic variable stress: gut-liver-brain axis disruption and the therapeutic promise of magnesium-L-theanine.Therapeutic advances in endocrinology and metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundChronic variable stress (CVS) has been associated with increased intestinal permeability and hepatic dysfunction, primarily through oxidative imbalance and metabolic dysregulation. This study evaluated the protective effects of nicotinamide riboside (NR) and magnesium-L-theanine (MgT) supplementation against CVS-induced intestinal and hepatic damage in rats. METHODS AND
resultsA total of 28 rats were randomly divided into four groups: Control, MgT + NR, Stress, and Stress + MgT + NR. NR (600 mg/kg/day) and MgT (400 mg/kg/day) were administered orally throughout the experimental period. The CVS model includes unpredictable stress factors such as water deprivation, exposure to cold, cage turning, exposure to intermittent flashing lights, physical restraint, wet bedding, and social isolation. Each of these factors was applied randomly every day for 40 days. CVS exposure significantly elevated serum glucose, corticosterone, ACTH, triglycerides, ALT, and AST levels, while reducing insulin, magnesium, and hepatic NAD⁺, NADPH, NAM, and NA concentrations. MgT + NR supplementation effectively reversed these changes. Moreover, it restored the hepatic expression of PPARγ, SIRT-1, GLUT2, and IRS-1, while downregulating the expression of FASN and SREBF1. In the jejunum, tight junction proteins (Claudin-1, Claudin-4, Occludin, ZO-1), mucin (MUC-2), glucose transporters (SGLT1, GLUT2), and nutrient carriers (PepT1, LAT2, EAAT3, FABP2, FATP4) were significantly improved with treatment. Histological analysis confirmed amelioration of CVS-induced liver steatosis and intestinal architectural damage.
conclusionThese findings suggest that combined NR and MgT supplementation mitigates stress-induced metabolic and structural alterations in the gut-liver axis, likely through the modulation of NAD⁺ metabolism and barrier function, and may serve as a promising trace element-based strategy for managing stress-related metabolic disorders.
Indexed as
Identifiers
41042405What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.